Your browser doesn't support javascript.
loading
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies.
Luke, Jason J; Piha-Paul, Sarina A; Medina, Theresa; Verschraegen, Claire F; Varterasian, Mary; Brennan, Aoife M; Riese, Richard J; Sokolovska, Anna; Strauss, James; Hava, David L; Janku, Filip.
Afiliación
  • Luke JJ; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
  • Piha-Paul SA; University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Medina T; University of Colorado School of Medicine, Aurora, Colorado.
  • Verschraegen CF; Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
  • Varterasian M; Ann Arbor Drug Safety, LLC, Ann Arbor, Michigan.
  • Brennan AM; Synlogic Inc., Cambridge, Massachusetts.
  • Riese RJ; Synlogic Inc., Cambridge, Massachusetts.
  • Sokolovska A; Synlogic Inc., Cambridge, Massachusetts.
  • Strauss J; Mary Crowley Cancer Research, Dallas, Texas.
  • Hava DL; Synlogic Inc., Cambridge, Massachusetts.
  • Janku F; University of Texas, MD Anderson Cancer Center, Houston, Texas.
Clin Cancer Res ; 29(13): 2435-2444, 2023 07 05.
Article en En | MEDLINE | ID: mdl-37227176
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Escherichia coli / Neoplasias Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Escherichia coli / Neoplasias Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article